This trial is unknown!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Carcinoma of the Oesophagus
and you are
over 18
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

The purpose of this study is to determine the Maximum Tolerated Dose (MTD) of olaparib in combination with radical radiotherapy in patients with oesophageal cancer who are unsuitable for platinum containing chemotherapy.

Provided treatments

  • Drug: Olaparib
  • Radiation: Radical external beam radiotherapy, 50Gy in 25 fractions

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01460888. The sponsor of the trial is The Christie NHS Foundation Trust and it is looking for 36 volunteers for the current phase.
Official trial title:
Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus. A Phase I Trial.